-
UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY)
Monday, May 2, 2011 - 5:31pm | 132Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration has approved Tradjenta™ tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA can...
-
UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly
Monday, May 2, 2011 - 3:20pm | 83The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes. Tradjenta was demonstrated to be safe and effective in eight double-blind, placebo-controlled clinical studies...
-
Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)
Monday, May 2, 2011 - 2:44pm | 21Lilly (NYSE: LLY), Boehringer Win FDA Approval For Diabetes Drug, Reported By Bloomberg
-
Earnings Preview: Pfizer (PFE)
Monday, May 2, 2011 - 2:09pm | 127Pfizer (NYSE: PFE) is set to report earnings tomorrow before the bell, and Wall Street will be looking to see how expiring drugs are going to affect the company's earnings going forward, as well as any more clarity on the breakup of the company. At last check, shares of Pfizer were up 7 cents to $...
-
Teva To Buy Taiyo Pharmaceutical For 40B Yen -Nikkei (TEVA)
Monday, May 2, 2011 - 1:12pm | 20Teva (NASDAQ: TEVA) to buy Taiyo Pharmaceutical for 40B Yen reports Nikkei.
-
Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Men's Rogaine Foam
Monday, May 2, 2011 - 12:25pm | 113Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Minoxidil Foam, a generic version of Men's Rogaine® Foam. Perrigo had been sued for patent infringement by...
-
Benzinga's Volume Movers (VLCM, CEPH, TLCR, HRBN)
Monday, May 2, 2011 - 10:47am | 160Volcom Inc (NASDAQ: VLCM) shares moved up 23.72% to $24.41 at 10:45 am. The volume of VLCM shares traded was 7274% higher than normal. PPR agreed to purchase Volcom for $607.5 million. Cephalon Inc (NASDAQ: CEPH) shares rose 5.00% to $80.87. The volume of CEPH shares traded was 1099% higher than...
-
Top Performing Industries For May 2 (NFLX, WYNN, FRX, RSH)
Monday, May 2, 2011 - 10:30am | 202At 10:25 am, the Dow rose 0.45% to 12,868.63, the broader Standard & Poor's 500 index moved up 0.44% to 1,369.67 and the NASDAQ composite index gained 0.37% to 2,884.13. The industries that are driving the market today are: Music & Video Stores: This industry jumped 1.94% by 10:25 am. The...
-
Spectrum Pharmaceuticals Up 12% (SPPI)
Monday, May 2, 2011 - 10:26am | 72Spectrum Pharmaceuticals (NASDAQ: SPPI) is up more than 12% in early trade after the company's Fusilev drug was approved by the FDA for colorectal cancer. Fusilev had already won approval for osteosarcoma, a common form of bone cancer. Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial...
-
News Summary
Monday, May 2, 2011 - 9:44am | 225Shares of Tenet Healthcare Corp (NYSE: THC) fell about 4.4% after Community Health Systems Inc (NYSE: CYH) raised its all-cash offer to acquire all outstanding shares of common stock of THC to $7.25 per share from $6 per share. Shares of Loews Corp (NYSE: L) dropped about 3.2% after the company...
-
Repros Therapeutics Provides Clinical Update for Androxal Study in Men With Type 2 Diabetes
Monday, May 2, 2011 - 9:31am | 124Repros Therapeutics Inc. (Nasdaq: RPRX) today provided a progress update for its Phase 2 clinical study of Androxal® in hypogonadal men with type 2 diabetes. Many men with secondary hypogonadism are also type 2 diabetic. The Company noted that 66 subjects have been randomized into the trial that is...
-
Teva Expects $1B After Closing, $500M of Cost Savings from Purchase (CEPH. TEVA)
Monday, May 2, 2011 - 9:00am | 78Teva (NASDAQ: TEVA) says, "Cephalon (NASDAQ: CEPH) enterprise value includes conversion of convertibles... Cephalon is `great strategic fit'... sees $500M of cost savings from Cephalon purchase... sees cost savings in third year after closing... expects to have $1 billion in cash after closing......
-
Benzinga's Top Pre-Market NASDAQ Gainers (TIVO, SPPI, CEPH, TLCR)
Monday, May 2, 2011 - 8:13am | 165TiVo Inc (NASDAQ: TIVO) shares surged 17.76% to $11.27 in the pre-market session. Dish Network (NASDAQ: DISH) and EchoStar (NASDAQ: SATS) will pay $500 million to TiVo in settlement over DVR technology. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) shares advanced 16.67% to $10.50 in the pre-market...
-
CEOWORLD Top five companies in the Internet Retail industry- EXPE, AMZN, DANG, PCLN, NFLX
Monday, May 2, 2011 - 8:06am | 963Expedia (EXPE)- Online travel agency Expedia Inc said its quarterly net profit fell on increased expenses related to technology investments and international expansion, but bookings rose 10 percent. First-quarter net profit slipped to $52 million, or 19 cents per share, from $59.4 million, or 20...
-
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
Monday, May 2, 2011 - 8:04am | 102Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on April 29, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 632,000 shares of common stock to 20 new employees. Each stock option has an exercise...